Literature DB >> 25693865

Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.

Ru Chen1, Jing Wang, Yuan Zhang, Shaowen Tang, Siyan Zhan.   

Abstract

Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is one of the leading adverse drug reactions during the course of tuberculosis treatment and poses a considerable challenge to clinicians and researchers. Previous studies have revealed the important contribution of drug metabolism and transporter enzymes to the complexity of ATDH. The emerging roles of immune response and oxidative stress resulting from reactive metabolite in the development of ATDH have also gained attention recently. Both non-genetic and genetic factors can have a significant impact on the susceptibility to ATDH, consequently altering the risk of hepatotoxicity in susceptible individuals. Non-genetic risk factors associated with ATDH include host factors, environment factors and drug-related factors. Genetic factors contributing to the susceptibility of ATDH involve genetic variations in bioactivation/toxification pathways via the cytochrome P450 enzymes (phase I), detoxification reactions by N-acetyl transferase 2, glutathione S-transferase and uridine diphosphate glucuronosyltransferase (phase II) and hepatic transport (phase III), together with immunological factors and antioxidant response. Better understanding of these factors may help to predict and prevent the occurrence of ATDH and develop more effective treatments. This review focuses on the mechanisms of ATDH and the key factors of susceptibility associated with drug metabolism, hepatic transport, immune response and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25693865     DOI: 10.1007/s00204-015-1473-1

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  11 in total

1.  CYP2S1 rs338599 polymorphism confers reduced risk to anti-tuberculosis drug-induced liver injury and may be a novel marker for its risk prediction.

Authors:  Liyuan Wang; Hui Wang; Ying Qi
Journal:  J Clin Lab Anal       Date:  2022-05-09       Impact factor: 3.124

2.  Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.

Authors:  Guo Chen; Shou-Quan Wu; Mei Feng; Yu Wang; Jing-Can Wu; Gui-Yi Ji; Miao-Miao Zhang; Qian-Qian Liu; Jian-Qing He
Journal:  Int J Immunopathol Pharmacol       Date:  2017-09-22       Impact factor: 3.219

3.  Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity.

Authors:  Yu Wang; Xi Xiang; Wei-Wei Huang; Andrew J Sandford; Shou-Quan Wu; Miao-Miao Zhang; Ming-Gui Wang; Guo Chen; Jian-Qing He
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

4.  The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study.

Authors:  Jin Hwa Song; Seo-Young Yoon; Tae Yun Park; Eun Young Heo; Deog Kyeom Kim; Hee Soon Chung; Jung-Kyu Lee
Journal:  Respir Res       Date:  2019-12-16

5.  NR1I2 genetic polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity: A systematic review and meta-analysis.

Authors:  Miaomiao Yang; Yunliang Qiu; Yanyu Jin; Wenpei Liu; Qingliang Wang; Honggang Yi; Shaowen Tang
Journal:  Pharmacol Res Perspect       Date:  2020-12

Review 6.  A Dual Role of Heme Oxygenase-1 in Tuberculosis.

Authors:  Sen Yang; Jing Ouyang; Yanqiu Lu; Vijay Harypursat; Yaokai Chen
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

7.  Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity.

Authors:  Shouquan Wu; You-Juan Wang; Xiaoyan Tang; Yu Wang; Jingcan Wu; Guiyi Ji; Miaomiao Zhang; Guo Chen; Qianqian Liu; Andrew J Sandford; Jian-Qing He
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

8.  Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.

Authors:  Zelalem Petros; Ming-Ta Michael Lee; Atsushi Takahashi; Yanfei Zhang; Getnet Yimer; Abiy Habtewold; Wondwossen Amogne; Getachew Aderaye; Ina Schuppe-Koistinen; Taisei Mushiroda; Eyasu Makonnen; Michiaki Kubo; Eleni Aklillu
Journal:  BMC Genomics       Date:  2016-09-26       Impact factor: 3.969

9.  Highlight report: Metabolomics in hepatotoxicity testing.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2017-12-21       Impact factor: 4.068

10.  Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.

Authors:  Eun Kyoung Chung; Jangik I Lee; Seungwon Yang; Se Jung Hwang; Jung Yun Park
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.